Abstract Body

We investigated potential drug-drug interactions between the most commonly used artemisinin-containing therapies artmether-lumefantrine (AL) or artesunate-amodiaquine (AS-AQ) and dolutegravir (DTG).

We undertook two pharmacokinetic (PK) studies in healthy Ugandan volunteers, using standard clinical treatment doses of AL and AS-AQ and 50mg of DTG once daily given with food. Rich PK sampling was performed after the final dose of AL or AS-AQ. Study A: DTG/AL interaction. Two-way cross-over study design (n=16) with 1:1 randomisation. Subjects received either 3 days of AL dosing or 6 days of DTG (to reach steady state) plus 3 days AL+DTG. Following washout (21 days), the opposite regimen was given. Study B: DTG/AS-AQ interaction. Parallel study design (n=30) due to the long half-life of the active AQ metabolite, desethylamodiaquine (DEAQ). 1:1 randomisation to either 3 days of AS-AQ alone or 7 days of DTG alone followed by 3 days AS-AQ + DTG. Clinical and laboratory adverse events (AE) were reported using DAIDS criteria. Artemether (ARM), artesunate (ARS), dihydroartemisinin (DHA), lumefantrine (LF), desbutyl-lumefantrine (DLF), amodiaquine (AQ) and DEAQ were measured over 0-264 h (study A) and 0-624 h (study B) using LC-MS. Noncompartmental analysis was performed (WinNonlin). Geometric mean ratios (GMR; 90% CI) for antimalarials +/- DTG for Cmax, Tmax and AUC to last measurable time point (AUClast) were computed in Study A, and Mann Whitney U tests compared these parameters in Study B.

PK parameters are presented in the Table. Study A: For ARM, GMR of Cmax without (N=7) and with DTG (N=7) was 0.87 (0.67-1.14), of Tmax was 1.06 (0.84-1.34) and of AUClast was 1.05 (0.84-1.32). For DHA, GMR of Cmax was 0.92 (0.79-1.07), for Tmax was 1.17 (0.92-1.49) and for AUClast was 0.92 (0.79-1.07). For LF, GMR of Cmax was 1.12 (0.97-1.29), for Tmax was 1.65 (1.02-2.69) and for AUClast was 1.10 (0.96-1.27). For DLF, GMR of Cmax was 0.96 (0.80-1.15), Tmax was 3.00 (2.06-4.36) and for AUClast was 0.96 (0.80-1.15). Study B: There were no statistically significant differences in AUClast for ARS (p=0.77), DHA (p=0.28), AQ (p=0.17) and DEAQ (p=0.69) between subjects administered AS-AQ alone (N=13) and those receiving DTG (N=12). No AEs ≥ grade 3 were observed in either study, and all drugs were well-tolerated.

Standard doses of the antimalarials AL and AS-AQ can be used in patients receiving DTG 50mg once daily.